AI Article Synopsis
- People who inject drugs (PWID) and prisoners are at high risk for HIV and HCV, prompting global health initiatives by UNAIDS and WHO to eliminate these diseases by 2030.
- In 2017, Germany's Federal Ministry of Health created a comprehensive strategy targeting HIV and HCV for these populations, marking progress five years later.
- To achieve elimination goals by 2030, Germany must enhance support for PWID and prisoners through effective harm reduction, diagnosis, and treatment efforts.
Article Abstract
People who inject drugs (PWID) and prisoners are considered key populations at risk for human immunodeficiency virus (HIV) and/or Hepatitis C Virus (HCV). In 2016, the Joint United Nations Program on HIV/AIDS (UNAIDS) was implemented to eliminate HIV and AIDS by 2030 and the World Health Organization (WHO) presented the first strategy to eliminate viral hepatitis by 2030 as well. Following the objectives of the WHO and the United Nations, the German Federal Ministry of Health (BMG) presented the first integrated overall strategy for HIV and HCV in 2017. This article discusses the situation of PWID and prisoners in Germany with regard to HIV and HCV five years after the adoption of this strategy, on the basis of available data and against the background of the most recent practice in the field. In order to meet the elimination goals by 2030, Germany will have to improve the situation of PWID and prisoners substantially, mainly through the implementation of evidence-based harm reduction measures as well as the promotion of diagnosis and treatment in prisons and in freedom.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100628 | PMC |
| http://dx.doi.org/10.1186/s12954-023-00774-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sero-prevalence of hepatitis B and C and HIV among students at the Federal University of Health Sciences, Azare.
Niger Med J
January 2025
Department of Obstetrics and Gynaecology, Federal University of Health Sciences, Azare, Bauchi State, Nigeria.
Background: Infection with the human immunodeficiency virus and hepatitis viruses B and C have been reported to be endemic in some Nigeria's institutions of higher learning. Several studies have reported varying prevalence rates for hepatitis B and C viruses and HIV among undergraduate students in Nigerian universities.
Methodology: A cross-sectional descriptive prevalence study of hepatitis B and C viruses and HIV among students at Federal University of Health Sciences, Azare conducted on the 2nd of December 2023.
Impact of Policy Changes Expanding Access to Direct-Acting Antivirals on Hepatitis C Virus-Related Hospitalizations in People With HIV: A Population-Based Study.
Open Forum Infect Dis
January 2025
Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada.
Background: The burden of hepatitis C virus (HCV)-related hospitalizations is substantial, particularly among people with HIV and HCV. In Ontario, Canada, use of direct-acting antivirals (DAAs) increased following policies removing fibrosis-stage restrictions and approving of pangenotypic agents in 2017 and 2018, respectively. We examined the impact of expanded DAA access on HCV-related hospitalizations in people with HIV.
View Article and Find Full Text PDFRisk Factors for Viral Coinfections in Blood Donors in Bahia, Brazil.
J Med Virol
February 2025
Programa de Pós-Graduação em Medicina e Saúde, Universidade Federal da Bahia, Salvador, Brazil.
Human Immunodeficiency Virus (HIV), Human T Lymphotropic Virus (HTLV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) coinfection may lead to disease progression or worsen its clinical presentation. Viral coinfections screening during blood donation is critical. To identify risk factors for coinfection among blood donors, we assessed the blood donations at the Fundação de Hematologia e Hemoterapia da Bahia, from 2008 to 2017.
View Article and Find Full Text PDFViral Infection Associated Membranous Nephropathy: Clinical Presentation and Outcomes.
Indian J Nephrol
August 2024
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Background: Viral infections can increase the likelihood of an individual developing membranous nephropathy (MN). Limited information is available regarding the treatment approaches for such cases. We conducted a review focusing on hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV)-associated MN.
View Article and Find Full Text PDFSyphilis-positive and false-positive trends among US blood donors, 2013-2023.
Transfusion
January 2025
Infectious Disease Consultant, North Potomac, Maryland, USA.
Background: US blood donors are tested for syphilis because the bacterial agent is transfusion transmissible. Here we describe trends over an 11-year period of donations positive for recent and past syphilis infections, and donations classified as syphilis false positive (FP).
Methods: Data from January 1, 2013, to December 31, 2023 (11 years) were compiled for all American Red Cross blood donations to evaluate demographics/characteristics and longitudinal trends in donors testing syphilis reactive/positive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!